Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . CGE 逸 大 健康 CGE HEALTHCARE CHINA GRAND PHARMACEUTICAL AND HEALTHCARE HOLDINGS LIMITED 遠大 醫藥 健康 控股 有限公司 * Financial Highlights ( Incorporated in Bermuda with limited liability ) ( Stock Code : 00512 ) 2021 INTERIM RESULTS ANNOUNCEMENT - For the six months ended 30 June 2021 , it recorded revenue of approximately HK $ 4,566.53 million ( for the six months ended 30 June 2020 : HK $ 3,255.78 million ) , representing an increase of approximately 40.3 % as compared to the corresponding period in 2020 . The total profit for the period attributable to owners of the Company for the six month ended 30 June 2021 amounted to approximately HK $ 1,202.54 million ( for the six months ended 30 June 2020 : HK $ 718.51 million ) , with an increment of approximately 67.4 % as compared with the corresponding period in 2020. If disregarding the gain from changes in fair value of investment in Telix , the total profit attributable to the owners of the Company for the period increased by approximately 26.3 % as compared to the corresponding period in 2020 . By virtue of the Group's further optimized earning structure and the Group's strategy of deepening innovation and developing barrier pharmaceutical products , the Group continuously promoted the sales of innovative high - barrier and high - margin products . During the Period , the Group's gross profit margin was approximately 63.3 % , which was 0.6 per cent points higher than the gross profit margin of 62.7 % for the corresponding period in 2020 . For the six months ended 30 June 2021 , our business continuously maintained constant growth , the Group invested a large amount of funds for product development , and invested a large amount of resources for the pre - clinical research , clinical trials , listing and registration phases of research projects , and reached agreements with a number of companies for obtaining the rights of R & D , manufacturing and commercialization of different products and for the consolidation of further cooperation , with a total investment amount of over HK $ 1.53 billion . 1